These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 38058357)

  • 21. Amyloid blood biomarker detects Alzheimer's disease.
    Nabers A; Perna L; Lange J; Mons U; Schartner J; Güldenhaupt J; Saum KU; Janelidze S; Holleczek B; Rujescu D; Hansson O; Gerwert K; Brenner H
    EMBO Mol Med; 2018 May; 10(5):. PubMed ID: 29626112
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cerebrospinal Fluid Biomarkers for Early and Differential Alzheimer's Disease Diagnosis.
    Bjerke M; Engelborghs S
    J Alzheimers Dis; 2018; 62(3):1199-1209. PubMed ID: 29562530
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Optimized Pre-analytical Handling Protocol for Blood-Based Biomarkers of Alzheimer's Disease.
    Jethwa A; Stöckl L
    Methods Mol Biol; 2024; 2785():67-73. PubMed ID: 38427188
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Critical Comparison of Different Biomarkers for Alzheimer's Disease in a Clinical Setting.
    Weise D; Tiepolt S; Awissus C; Hoffmann KT; Lobsien D; Kaiser T; Barthel H; Sabri O; Gertz HJ
    J Alzheimers Dis; 2015; 48(2):425-32. PubMed ID: 26402006
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Evolution of Diagnostic Boundaries of Alzheimer's Disease and Novel Therapeutic Options: Эволюция диагностических границ болезни Альцгеймера и новые терапевтические возможности.
    Gavrilova S
    Consort Psychiatr; 2022; 3(1):8-15. PubMed ID: 39045353
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Moving fluid biomarkers for Alzheimer's disease from research tools to routine clinical diagnostics.
    Zetterberg H; Blennow K
    Mol Neurodegener; 2021 Feb; 16(1):10. PubMed ID: 33608044
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Optimising Alzheimer's Disease Diagnosis and Treatment: Assessing Cost-Utility of Integrating Blood Biomarkers in Clinical Practice for Disease-Modifying Treatment.
    Aye S; Handels R; Winblad B; Jönsson L
    J Prev Alzheimers Dis; 2024; 11(4):928-942. PubMed ID: 39044504
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Clinical Use of Alzheimer's Disease Biomarkers in Patients with Mild Cognitive Impairment: A European Alzheimer's Disease Consortium Survey.
    Caprioglio C; Garibotto V; Jessen F; Frölich L; Allali G; Assal F; Frisoni GB; Altomare D;
    J Alzheimers Dis; 2022; 89(2):535-551. PubMed ID: 35912743
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease Pathology.
    Ashton NJ; Brum WS; Di Molfetta G; Benedet AL; Arslan B; Jonaitis E; Langhough RE; Cody K; Wilson R; Carlsson CM; Vanmechelen E; Montoliu-Gaya L; Lantero-Rodriguez J; Rahmouni N; Tissot C; Stevenson J; Servaes S; Therriault J; Pascoal T; Lleó A; Alcolea D; Fortea J; Rosa-Neto P; Johnson S; Jeromin A; Blennow K; Zetterberg H
    JAMA Neurol; 2024 Mar; 81(3):255-263. PubMed ID: 38252443
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Health System Change for Alzheimer's Disease-Modifying Therapies in Canada: Beginning the Discussion.
    Frank A; Ismail Z; Wilson M; Gauthier S; Verret L; Hsiung GR; Borrie M
    Can J Neurol Sci; 2023 Dec; ():1-9. PubMed ID: 38052729
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Alzheimer's disease and blood-based biomarkers - potential contexts of use.
    Zvěřová M
    Neuropsychiatr Dis Treat; 2018; 14():1877-1882. PubMed ID: 30050302
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup.
    Jack CR; Andrews JS; Beach TG; Buracchio T; Dunn B; Graf A; Hansson O; Ho C; Jagust W; McDade E; Molinuevo JL; Okonkwo OC; Pani L; Rafii MS; Scheltens P; Siemers E; Snyder HM; Sperling R; Teunissen CE; Carrillo MC
    Alzheimers Dement; 2024 Aug; 20(8):5143-5169. PubMed ID: 38934362
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study.
    Li QX; Villemagne VL; Doecke JD; Rembach A; Sarros S; Varghese S; McGlade A; Laughton KM; Pertile KK; Fowler CJ; Rumble RL; Trounson BO; Taddei K; Rainey-Smith SR; Laws SM; Robertson JS; Evered LA; Silbert B; Ellis KA; Rowe CC; Macaulay SL; Darby D; Martins RN; Ames D; Masters CL; Collins S;
    J Alzheimers Dis; 2015; 48(1):175-87. PubMed ID: 26401938
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Plasma p-tau231: a new biomarker for incipient Alzheimer's disease pathology.
    Ashton NJ; Pascoal TA; Karikari TK; Benedet AL; Lantero-Rodriguez J; Brinkmalm G; Snellman A; Schöll M; Troakes C; Hye A; Gauthier S; Vanmechelen E; Zetterberg H; Rosa-Neto P; Blennow K
    Acta Neuropathol; 2021 May; 141(5):709-724. PubMed ID: 33585983
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer's Disease Neuroimaging Initiative.
    Karikari TK; Benedet AL; Ashton NJ; Lantero Rodriguez J; Snellman A; Suárez-Calvet M; Saha-Chaudhuri P; Lussier F; Kvartsberg H; Rial AM; Pascoal TA; Andreasson U; Schöll M; Weiner MW; Rosa-Neto P; Trojanowski JQ; Shaw LM; Blennow K; Zetterberg H;
    Mol Psychiatry; 2021 Feb; 26(2):429-442. PubMed ID: 33106600
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical application of CSF biomarkers for Alzheimer's disease: From rationale to ratios.
    Bouwman FH; Frisoni GB; Johnson SC; Chen X; Engelborghs S; Ikeuchi T; Paquet C; Ritchie C; Bozeat S; Quevenco FC; Teunissen C
    Alzheimers Dement (Amst); 2022; 14(1):e12314. PubMed ID: 35496374
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A blood-based diagnostic test incorporating plasma Aβ42/40 ratio, ApoE proteotype, and age accurately identifies brain amyloid status: findings from a multi cohort validity analysis.
    West T; Kirmess KM; Meyer MR; Holubasch MS; Knapik SS; Hu Y; Contois JH; Jackson EN; Harpstrite SE; Bateman RJ; Holtzman DM; Verghese PB; Fogelman I; Braunstein JB; Yarasheski KE
    Mol Neurodegener; 2021 May; 16(1):30. PubMed ID: 33933117
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Systematic Review of Clinical Practice Guidelines for Alzheimer's Disease and Strategies for Future Advancements.
    Tahami Monfared AA; Phan NTN; Pearson I; Mauskopf J; Cho M; Zhang Q; Hampel H
    Neurol Ther; 2023 Aug; 12(4):1257-1284. PubMed ID: 37261607
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Correcting for the Absence of a Gold Standard Improves Diagnostic Accuracy of Biomarkers in Alzheimer's Disease.
    Coart E; Barrado LG; Duits FH; Scheltens P; van der Flier WM; Teunissen CE; van der Vies SM; Burzykowski T;
    J Alzheimers Dis; 2015; 46(4):889-99. PubMed ID: 25869788
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biomarkers for the Early Detection and Progression of Alzheimer's Disease.
    Counts SE; Ikonomovic MD; Mercado N; Vega IE; Mufson EJ
    Neurotherapeutics; 2017 Jan; 14(1):35-53. PubMed ID: 27738903
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.